Top Dividend Stocks to Buy and Hold Forever
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Fool
- AbbVie's Dividend King Status: AbbVie (ABBV) has increased its dividend for 53 consecutive years, with a current yield of approximately 3.2%, significantly higher than the S&P 500 average, demonstrating its strong competitive position and stability in the pharmaceutical market.
- Coca-Cola's Growth Potential: Coca-Cola (KO), a Dividend King, has raised its dividend for 63 years, currently yielding 2.8%, slightly below the 10-year average, yet with only a 7% market share in emerging markets, it has substantial growth opportunities ahead.
- Attractiveness of Realty Income: Realty Income (O), while not a Dividend King, has increased its dividend for over 30 years, boasting a yield of 5.3% and paying monthly dividends, showcasing its stable cash flow and investment appeal.
- Long-term Stability and Returns: AbbVie, Coca-Cola, and Realty Income have all exhibited low volatility and consistent positive returns over the decades, indicating their reliability in providing steady income for investors in uncertain market conditions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
